We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+32.6%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$9.65B
AUM Growth
+$1.82B
Cap. Flow
+$94.6M
Cap. Flow %
0.98%
Top 10 Hldgs %
77.89%
Holding
99
New
5
Increased
16
Reduced
3
Closed
6

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$62M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$37.7M
3
IMVT icon
Immunovant
IMVT
+$22.4M
4
BCAX
Bicara Therapeutics
BCAX
+$21.3M
5
SMMT icon
Summit Therapeutics
SMMT
+$16.8M

Top Sells

Rank Stock Value
1
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$28M
2
LONA
LeonaBio Inc
LONA
+$8.36M
3
TLIS
Talis Biomedical Corporation Common Stock
TLIS
+$4.4M
4
ADAP
Adaptimmune Therapeutics
ADAP
+$2.28M
5
SAGE
Sage Therapeutics
SAGE
+$1.86M

Sector Composition

Rank Sector Weight
1 Healthcare 98.95%
2 Financials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELVN icon
76
Enliven Therapeutics
ELVN
$3.79B
$2.93M 0.03%
114,833
– –
CMPX icon
77
Compass Therapeutics
CMPX
$362M
$2.87M 0.03%
1,557,630
– –
WVE icon
78
Wave Life Sciences
WVE
$1.11B
$2.82M 0.03%
+344,063
New +$2.06M
MRSN
79
DELISTED
Mersana Therapeutics
MRSN
$2.05M 0.02%
43,445
– –
NAMS icon
80
NewAmsterdam Pharma
NAMS
$3.25B
$1.61M 0.02%
96,711
-116
-0.1% -$2.01K
IPSC icon
81
Century Therapeutics
IPSC
$368M
$1.36M 0.01%
797,460
– –
VTVT icon
82
vTv Therapeutics
VTVT
$124M
$1.32M 0.01%
97,314
– –
JBIO
83
Jade Biosciences
JBIO
$1.19B
$1.31M 0.01%
17,970
– –
PFE icon
84
Pfizer
PFE
$143B
$1.01M 0.01%
35,000
– –
TARA icon
85
Protara Therapeutics
TARA
$216M
$982K 0.01%
536,832
– –
ALGS icon
86
Aligos Therapeutics
ALGS
$26.1M
$719K 0.01%
83,055
-1
-0% -$12
BCRX icon
87
BioCryst Pharmaceuticals
BCRX
$2.45B
$576K 0.01%
75,778
– –
PMVP icon
88
PMV Pharmaceuticals
PMVP
$57.1M
$480K 0.01%
322,024
– –
FHTX icon
89
Foghorn Therapeutics
FHTX
$279M
$419K ﹤0.01%
45,027
– –
ACRV icon
90
Acrivon Therapeutics
ACRV
$62.1M
$370K ﹤0.01%
52,885
– –
TYRA icon
91
Tyra Biosciences
TYRA
$1.85B
$249K ﹤0.01%
10,607
– –
SRZNW icon
92
Surrozen Inc Warrant
SRZNW
$36.6K
$8.58K ﹤0.01%
833,333
– –
ADAP
93
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-2,343,695
Closed -$2.28M
LONA
94
LeonaBio Inc
LONA
$67M
– –
-315,381
Closed -$8.36M
SAGE
95
DELISTED
Sage Therapeutics
SAGE
– –
-171,026
Closed -$1.86M
ACHL
96
DELISTED
Achilles Therapeutics
ACHL
– –
-1,108,767
Closed -$904K
TLIS
97
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
– –
-508,323
Closed -$4.4M
CERE
98
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
– –
-683,588
Closed -$28M
1 2 3
4

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2024 Portfolio in Review

As of Q3 2024, Baker Bros. Advisors held 99 positions worth $9.65B, up 23% from $7.83B the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Baker Bros. Advisors's Q3 2024 filing shows 5 new, 16 increased, 3 reduced and 6 closed positions. Its largest new stake was Bicara Therapeutics: 833,333 shares worth $21.2M. The largest sale was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $28M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q3 2024 buy was Bicara Therapeutics: 833,333 shares worth $21.2M.
  • Baker Bros. Advisors added most to Insmed in Q3 2024, an estimated $62M increase.
  • Baker Bros. Advisors's biggest Q3 2024 reduction was NewAmsterdam Pharma, cutting an estimated $2.01K.
  • Baker Bros. Advisors fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2024, selling an estimated $28M.
  • Baker Bros. Advisors's ten largest holdings make up 78% of its $9.65B portfolio in Q3 2024.
  • Baker Bros. Advisors opened 5 new positions and closed 6 in Q3 2024.
  • Baker Bros. Advisors's portfolio value rose 23% quarter-over-quarter to $9.65B.

Based on Baker Bros. Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.